安科生物：独家代理重组人卵泡刺激素产品在中国大陆及港澳台地区的销售及营销推广

Core Viewpoint - Anke Biotech (300009) has signed an exclusive agency agreement with Shengji Pharmaceutical for the sales and marketing of SJ02, a recombinant human follicle-stimulating hormone-CTP fusion protein injection, in mainland China and Hong Kong, Macau, and Taiwan [1] Group 1 - SJ02, in combination with gonadotropin-releasing hormone antagonists, is intended for controlled ovarian stimulation and has the potential to be the first long-acting FSH-CTP approved in China [1] - The drug registration application was submitted to the National Medical Products Administration in December 2023, indicating a significant step towards market entry [1] - The collaboration aims to accelerate the commercialization of SJ02 in the Chinese market, enhancing the company's product portfolio in the assisted reproduction field and increasing its industry influence and profit growth [1]